Tempest Therapeutics Inc (TPST)

$1.04 +0.02 (1.96%)
Market Cap 16.62M
Revenue (ttm) 0.00
Net Income (ttm) -26.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 133,800
Avg Vol 234,692
Day's Range N/A - N/A
Shares Out 15.98M
Stochastic %K 17%
Beta -1.72
Analysts Sell
Price Target $11.00

Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating va...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 798 8589
Address:
2000 Sierra Point Parkway, Suite 400, Brisbane, United States
lousjamsession
lousjamsession Aug. 24 at 3:36 PM
$TPST
0 · Reply
Michl2000
Michl2000 Aug. 24 at 2:09 PM
$TPST what are those idiots doing since 18 months. Obviously nothing but diluting.
0 · Reply
Michl2000
Michl2000 Aug. 24 at 12:34 PM
$TPST today another great day for $TPST 🙈💩💩💩🙈
0 · Reply
Michl2000
Michl2000 Aug. 22 at 10:01 PM
$TPST dear audience, here' s my saturday-💩💩💩💩.
0 · Reply
josegodoy
josegodoy Aug. 22 at 6:08 PM
$TPST for entertainment ONLY - she’s on the cusp 🎲 🎲 Not saying we are going here just yet, but… 1) looking for $2-ish…. 2) if for whatever reason we get ($2.50-$3.00)* = a message to me (& the market in general) of higher prices in the near future *hitting this range adds validity to a shady looking formation The prices below are just as likely: - Gap: $0.91-ish - Recent low: $0.84-ish For entertainment ONLY
0 · Reply
lousjamsession
lousjamsession Aug. 22 at 4:41 PM
$TPST pretty consistent on Saturdays
1 · Reply
Xamayca
Xamayca Aug. 22 at 4:37 PM
$TPST completion of all manufacturing in preparation for IND registration should be completed by 9/30 latest I would expect a PR on that .
0 · Reply
USAEquityResearch
USAEquityResearch Aug. 22 at 7:05 AM
$TPST 📊 USAEquityResearch ▲ 1.04 (+1.96%) Trend: Cautiously bullish ↗️ RSI (14): 60.3 — strong momentum, approaching overbought MACD: bullish, above signal line and rising Volume: below average 📌 Key Levels Resistance: 1.21 | Support: 0.86 20-MA: 0.99 | 50-MA: 1.05 💼 Fundamentals Mkt Cap: $16.62M FCF: $-11.14M (-0.70/sh) Total Debt: $7.56M Educational content only. Not financial advice.
0 · Reply
Xamayca
Xamayca Aug. 21 at 9:49 PM
$TPST Ober 2 mil shares dilutesd since Lincoln Park announcement
1 · Reply
Michl2000
Michl2000 Aug. 21 at 9:09 PM
$TPST great! 💩💩💩💩💩💩💩💩
0 · Reply
Latest News on TPST
Tempest Therapeutics files to sell 8.91M shares of common stock for holders

2026-08-21T20:50:21.000Z - 2 days ago

Tempest Therapeutics files to sell 8.91M shares of common stock for holders

Tempest Therapeutics Registration statement: Registration filing

Aug 21, 2026, 8:00 AM EDT - 3 days ago

Tempest Therapeutics Registration statement: Registration filing

Tempest Therapeutics Proxy statement: Proxy filing

Aug 18, 2026, 8:00 AM EDT - 6 days ago

Tempest Therapeutics Proxy statement: Proxy filing

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 13, 2026, 4:25 PM EDT - 10 days ago

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Tempest Therapeutics Earnings release: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 10 days ago

Tempest Therapeutics Earnings release: Q2 2026

Tempest Therapeutics Quarterly report: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 10 days ago

Tempest Therapeutics Quarterly report: Q2 2026

Tempest Therapeutics Proxy statement: Proxy filing

Jul 28, 2026, 8:00 AM EDT - 27 days ago

Tempest Therapeutics Proxy statement: Proxy filing

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

Jul 21, 2026, 7:00 AM EDT - 4 weeks ago

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

Tempest Therapeutics Proxy statement: Proxy filing

Jul 17, 2026, 8:00 AM EDT - 5 weeks ago

Tempest Therapeutics Proxy statement: Proxy filing

Tempest Therapeutics Slides: Corporate presentation

Jul 15, 2026, 8:00 AM EDT - 5 weeks ago

Tempest Therapeutics Slides: Corporate presentation

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

Jul 15, 2026, 7:00 AM EDT - 5 weeks ago

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

Tempest Therapeutics Proxy statement: Proxy filing

Jul 7, 2026, 8:00 AM EDT - 6 weeks ago

Tempest Therapeutics Proxy statement: Proxy filing

Tempest Therapeutics registers to sell 2.43M shares of common stock for holders

2026-06-26T20:10:33.000Z - 2 months ago

Tempest Therapeutics registers to sell 2.43M shares of common stock for holders

Tempest Therapeutics Registration statement: Registration filing

Jun 26, 2026, 8:00 AM EDT - 2 months ago

Tempest Therapeutics Registration statement: Registration filing

Tempest Therapeutics Proxy statement: Proxy filing

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Tempest Therapeutics Proxy statement: Proxy filing

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

Jun 4, 2026, 4:37 PM EDT - 2 months ago

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

MD

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

May 29, 2026, 8:00 AM EDT - 3 months ago

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

Tempest Therapeutics Proxy statement: Proxy filing

May 29, 2026, 8:00 AM EDT - 3 months ago

Tempest Therapeutics Proxy statement: Proxy filing

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026, 4:15 PM EDT - 3 months ago

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Tempest Therapeutics Earnings release: Q1 2026

May 14, 2026, 4:00 PM EDT - 3 months ago

Tempest Therapeutics Earnings release: Q1 2026

Tempest Therapeutics Quarterly report: Q1 2026

May 14, 2026, 4:00 PM EDT - 3 months ago

Tempest Therapeutics Quarterly report: Q1 2026

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

May 6, 2026, 7:00 AM EDT - 3 months ago

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

Tempest Therapeutics Slides: Corporate presentation

May 6, 2026, 7:00 AM EDT - 3 months ago

Tempest Therapeutics Slides: Corporate presentation

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

Tempest Therapeutics provides update on development of TPST-2003

2026-04-22T12:30:21.000Z - 4 months ago

Tempest Therapeutics provides update on development of TPST-2003

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Apr 14, 2026, 8:00 AM EDT - 4 months ago

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Tempest Therapeutics Registration statement: Registration filing

Apr 2, 2026, 8:00 AM EDT - 5 months ago

Tempest Therapeutics Registration statement: Registration filing

Tempest Therapeutics files to sell 2.78M shares of common stock for holders

2026-04-02T10:11:28.000Z - 5 months ago

Tempest Therapeutics files to sell 2.78M shares of common stock for holders

Tempest Therapeutics files to sell 8.27M shares of common stock for holders

2026-03-30T22:05:33.000Z - 5 months ago

Tempest Therapeutics files to sell 8.27M shares of common stock for holders

Tempest Reports Year End 2025 Financial Results and Provides Business Update

Mar 30, 2026, 9:00 AM EDT - 5 months ago

Tempest Reports Year End 2025 Financial Results and Provides Business Update

Tempest Therapeutics Annual report: Q4 2025

Mar 30, 2026, 8:30 AM EDT - 5 months ago

Tempest Therapeutics Annual report: Q4 2025

Tempest Therapeutics Earnings release: Q4 2025

Mar 30, 2026, 8:30 AM EDT - 5 months ago

Tempest Therapeutics Earnings release: Q4 2025

Tempest Therapeutics Registration statement: Registration filing

Mar 30, 2026, 8:00 AM EDT - 5 months ago

Tempest Therapeutics Registration statement: Registration filing

Tempest Therapeutics Announces Up To $6 Million Private Placement

Mar 23, 2026, 8:00 AM EDT - 5 months ago

Tempest Therapeutics Announces Up To $6 Million Private Placement

Tempest, Cincinnati Children’s AGCTC partner for TPST-2003 registrational study

2026-03-11T12:06:24.000Z - 5 months ago

Tempest, Cincinnati Children’s AGCTC partner for TPST-2003 registrational study

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

Mar 11, 2026, 8:00 AM EDT - 5 months ago

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

Tempest Therapeutics announces data from REDEEM-1 Phase 1/2a trial on TPST-2003

2026-02-25T13:24:11.000Z - 6 months ago

Tempest Therapeutics announces data from REDEEM-1 Phase 1/2a trial on TPST-2003

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

Feb 25, 2026, 7:59 AM EST - 6 months ago

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

Feb 11, 2026, 6:59 AM EST - 6 months ago

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

Feb 4, 2026, 4:47 PM EST - 7 months ago

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

Tempest Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

2026-01-22T11:12:02.000Z - 7 months ago

Tempest Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

Jan 20, 2026, 5:20 PM EST - 7 months ago

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

Tempest Therapeutics Proxy statement: Proxy Filing

Dec 31, 2025, 7:00 AM EST - 8 months ago

Tempest Therapeutics Proxy statement: Proxy Filing

Tempest Therapeutics files to sell 1.17M shares of common stock for holders

2025-12-09T21:55:14.000Z - 9 months ago

Tempest Therapeutics files to sell 1.17M shares of common stock for holders

Tempest Therapeutics Registration statement: Registration Filing

Dec 9, 2025, 7:00 AM EST - 9 months ago

Tempest Therapeutics Registration statement: Registration Filing

Tempest Therapeutics Proxy statement: Proxy Filing

Dec 2, 2025, 7:00 AM EST - 9 months ago

Tempest Therapeutics Proxy statement: Proxy Filing

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Nov 26, 2025, 4:05 PM EST - 9 months ago

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Tempest Therapeutics prices 1.17M shares at $3.63 in registered direct offering

2025-11-25T13:05:18.000Z - 9 months ago

Tempest Therapeutics prices 1.17M shares at $3.63 in registered direct offering

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Nov 25, 2025, 8:00 AM EST - 9 months ago

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Tempest announces acquisition of new dual-CAR T programs from Factor Bioscience

2025-11-19T14:11:00.000Z - 9 months ago

Tempest announces acquisition of new dual-CAR T programs from Factor Bioscience

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

Nov 19, 2025, 9:00 AM EST - 9 months ago

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

BTX

Tempest Therapeutics Proxy statement: Proxy Filing

Nov 19, 2025, 7:00 AM EST - 9 months ago

Tempest Therapeutics Proxy statement: Proxy Filing

Tempest Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 9:00 AM EST - 10 months ago

Tempest Therapeutics Quarterly report: Q3 2025

Tempest Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 9:00 AM EST - 10 months ago

Tempest Therapeutics Earnings release: Q3 2025

Tempest Therapeutics reports Q3 EPS (79c) vs ($5.32) last year

2025-11-05T13:36:56.000Z - 10 months ago

Tempest Therapeutics reports Q3 EPS (79c) vs ($5.32) last year

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 8:30 AM EST - 10 months ago

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

Tempest Therapeutics reports Q2 EPS ($2.07), consensus ($2.65)

2025-08-11T20:55:19.000Z - 1 year ago

Tempest Therapeutics reports Q2 EPS ($2.07), consensus ($2.65)

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 4:12 PM EDT - 1 year ago

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Tempest Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Quarterly report: Q2 2025

Tempest Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Earnings release: Q2 2025

Tempest Therapeutics receives NMPA clearance to proceed with amezalpat trial

2025-06-30T14:37:56.000Z - 1 year ago

Tempest Therapeutics receives NMPA clearance to proceed with amezalpat trial

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Jun 30, 2025, 8:00 AM EDT - 1 year ago

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Tempest prices 739,000 shares at $6.25 in registered direct offering

2025-06-11T12:20:36.000Z - 1 year ago

Tempest prices 739,000 shares at $6.25 in registered direct offering

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Tempest Therapeutics receives ODD from EMA for amezalpat

2025-06-05T12:05:21.000Z - 1 year ago

Tempest Therapeutics receives ODD from EMA for amezalpat

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:28 PM EDT - 1 year ago

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

Tempest Therapeutics Quarterly report: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Quarterly report: Q1 2025

Tempest Therapeutics Earnings release: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Earnings release: Q1 2025

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Apr 28, 2025, 4:05 PM EDT - 1 year ago

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Apr 9, 2025, 4:30 PM EDT - 1 year ago

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Tempest Therapeutics Slides: Corporate Presentation

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Tempest Therapeutics Slides: Corporate Presentation

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Mar 27, 2025, 4:10 PM EDT - 1 year ago

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Tempest Therapeutics Annual report: Q4 2024

Mar 27, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Annual report: Q4 2024

Tempest Therapeutics Earnings release: Q4 2024

Mar 27, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Earnings release: Q4 2024

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Mar 13, 2025, 8:00 AM EDT - 1 year ago

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Feb 10, 2025, 8:00 AM EST - 1 year ago

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 7, 2025, 4:30 PM EST - 1 year ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest Therapeutics Registration statement: Registration Filing

Jan 24, 2025, 7:00 AM EST - 1 year ago

Tempest Therapeutics Registration statement: Registration Filing

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Jan 6, 2025, 8:00 AM EST - 1 year ago

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Tempest Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 9:00 AM EST - 1 year ago

Tempest Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 4:30 PM EST - 1 year ago

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 12, 2024, 4:21 PM EST - 1 year ago

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Tempest Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Tempest Therapeutics Earnings release: Q3 2024

Tempest Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Tempest Therapeutics Quarterly report: Q3 2024

Tempest Therapeutics Proxy statement: Proxy Filing

Nov 12, 2024, 7:00 AM EST - 1 year ago

Tempest Therapeutics Proxy statement: Proxy Filing

Tempest Therapeutics Proxy statement: Proxy Filing

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Tempest Therapeutics Proxy statement: Proxy Filing

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Oct 10, 2024, 7:01 AM EDT - 2 years ago

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 20, 2024, 4:30 PM EDT - 2 years ago

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tempest Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 7:00 AM EDT - 2 years ago

Tempest Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 8:00 AM EDT - 2 years ago

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 4:56 PM EDT - 2 years ago

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Tempest Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Quarterly report: Q2 2024

Tempest Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Earnings release: Q2 2024

Tempest Therapeutics Registration statement: Registration Filing

Jul 19, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Registration statement: Registration Filing

Tempest Therapeutics Transcript: Study Update

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Transcript: Study Update

Tempest Therapeutics Slides: Study Update

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Slides: Study Update

Tempest Therapeutics Press release: Study Update

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Press release: Study Update

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Jun 18, 2024, 6:22 PM EDT - 2 years ago

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Tempest Therapeutics Transcript: Jefferies Global Healthcare Conference

Jun 5, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Transcript: Jefferies Global Healthcare Conference

Tempest Therapeutics Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

May 29, 2024, 2:00 PM EDT - 2 years ago

Tempest Therapeutics Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:29 PM EDT - 2 years ago

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Tempest Therapeutics Quarterly report: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Quarterly report: Q1 2024

Tempest Therapeutics Earnings release: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Earnings release: Q1 2024

Tempest Therapeutics Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Proxy statement: Proxy Filing

Tempest Therapeutics Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Proxy statement: Proxy Filing

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Apr 9, 2024, 8:00 AM EDT - 2 years ago

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Mar 19, 2024, 4:25 PM EDT - 2 years ago

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Tempest Therapeutics Earnings release: Q4 2023

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Earnings release: Q4 2023

Tempest Therapeutics Annual report: Q4 2023

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Annual report: Q4 2023

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Mar 5, 2024, 4:30 PM EST - 2 years ago

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Tempest Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 4, 2024, 9:10 AM EST - 2 years ago

Tempest Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Tempest Therapeutics Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 28, 2023, 3:00 PM EST - 2 years ago

Tempest Therapeutics Transcript: Piper Sandler 35th Annual Healthcare Conference

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 8:00 AM EST - 3 years ago

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

lousjamsession
lousjamsession Aug. 24 at 3:36 PM
$TPST
0 · Reply
Michl2000
Michl2000 Aug. 24 at 2:09 PM
$TPST what are those idiots doing since 18 months. Obviously nothing but diluting.
0 · Reply
Michl2000
Michl2000 Aug. 24 at 12:34 PM
$TPST today another great day for $TPST 🙈💩💩💩🙈
0 · Reply
Michl2000
Michl2000 Aug. 22 at 10:01 PM
$TPST dear audience, here' s my saturday-💩💩💩💩.
0 · Reply
josegodoy
josegodoy Aug. 22 at 6:08 PM
$TPST for entertainment ONLY - she’s on the cusp 🎲 🎲 Not saying we are going here just yet, but… 1) looking for $2-ish…. 2) if for whatever reason we get ($2.50-$3.00)* = a message to me (& the market in general) of higher prices in the near future *hitting this range adds validity to a shady looking formation The prices below are just as likely: - Gap: $0.91-ish - Recent low: $0.84-ish For entertainment ONLY
0 · Reply
lousjamsession
lousjamsession Aug. 22 at 4:41 PM
$TPST pretty consistent on Saturdays
1 · Reply
Xamayca
Xamayca Aug. 22 at 4:37 PM
$TPST completion of all manufacturing in preparation for IND registration should be completed by 9/30 latest I would expect a PR on that .
0 · Reply
USAEquityResearch
USAEquityResearch Aug. 22 at 7:05 AM
$TPST 📊 USAEquityResearch ▲ 1.04 (+1.96%) Trend: Cautiously bullish ↗️ RSI (14): 60.3 — strong momentum, approaching overbought MACD: bullish, above signal line and rising Volume: below average 📌 Key Levels Resistance: 1.21 | Support: 0.86 20-MA: 0.99 | 50-MA: 1.05 💼 Fundamentals Mkt Cap: $16.62M FCF: $-11.14M (-0.70/sh) Total Debt: $7.56M Educational content only. Not financial advice.
0 · Reply
Xamayca
Xamayca Aug. 21 at 9:49 PM
$TPST Ober 2 mil shares dilutesd since Lincoln Park announcement
1 · Reply
Michl2000
Michl2000 Aug. 21 at 9:09 PM
$TPST great! 💩💩💩💩💩💩💩💩
0 · Reply
TwongStocks
TwongStocks Aug. 21 at 8:57 PM
$TPST Daily purchase caps for LP: Max of 60k shares per day. Can be increased under the following conditions: • 70k daily max if TPST is above $1 • 80k daily max if TPST is above $2 In any case the max they can sell in a single purchase must be less than $500K. They can also do "Acceleerated Purchases" to sell more shares if certain volume requirements are met.
0 · Reply
TwongStocks
TwongStocks Aug. 21 at 8:51 PM
$TPST Registration statement filed for the LP purchase agreement https://www.sec.gov/Archives/edgar/data/1544227/000119312526361240/d181522ds1.htm 16,539,767 shares of common stock outstanding as of August 19, 2026 (which includes the 560,356 Initial Commitment Shares).
0 · Reply
Sauhaufen
Sauhaufen Aug. 21 at 7:48 PM
$TPST
1 · Reply
lousjamsession
lousjamsession Aug. 21 at 5:07 PM
$TPST
0 · Reply
Onedaytolive
Onedaytolive Aug. 21 at 4:48 PM
$TPST The CEO of Angel is a pioneer in mRNA research. There’s no doubt that the news about Moderna has inspired him greatly, and his decision to take this risk has once again proven to be the right one. All that’s left is to find investors who share his vision.
1 · Reply
josegodoy
josegodoy Aug. 21 at 6:33 AM
$TPST stay relaxed An opinion
0 · Reply
Michl2000
Michl2000 Aug. 20 at 7:42 PM
$TPST either the "old" pipeline 1120 and/or 1495 hit, or this stock is worthless
0 · Reply
Michl2000
Michl2000 Aug. 20 at 6:00 PM
$TPST 💩💩💩
0 · Reply
TwongStocks
TwongStocks Aug. 20 at 4:07 PM
$TPST "The Company has agreed to file such registration statement with the Securities and Exchange Commission (the “SEC”) not later than 10 days after the date of execution of the Purchase Agreement and the Registration Rights Agreement. " Registration statement for the Lincoln Park Purchase Agreement will have to be filed soon. TPST can begin selling shares to LP after the registration statement is declared effective by the SEC.
0 · Reply
Sauhaufen
Sauhaufen Aug. 20 at 2:45 PM
$TPST
1 · Reply
lousjamsession
lousjamsession Aug. 20 at 2:33 PM
$TPST .
0 · Reply
lousjamsession
lousjamsession Aug. 20 at 2:33 PM
$TPST
0 · Reply